SOX-10 expression in cutaneous myoepitheliomas and mixed tumors
Version of Record online: 3 FEB 2014
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
Journal of Cutaneous Pathology
Volume 41, Issue 4, pages 353–363, April 2014
How to Cite
SOX-10 expression in cutaneous myoepitheliomas and mixed tumors., , , , , , .
- Issue online: 21 MAR 2014
- Version of Record online: 3 FEB 2014
- Accepted manuscript online: 14 DEC 2013 07:37AM EST
- Manuscript Accepted: 7 DEC 2013
- Manuscript Revised: 22 NOV 2013
- Manuscript Received: 18 SEP 2013
- adnexal neoplasm;
- cutaneous adnexal neoplasms;
- cutaneous neoplasm;
SOX-10 expression can be demonstrated by immunohistochemistry in salivary gland myoepitheliomas, but its expression in cutaneous myoepitheliomas and in cutaneous mixed tumors with prominent myoepithelial cells has not been studied.
We assessed the staining pattern of SOX-10 in five cutaneous myoepitheliomas and six cutaneous mixed tumors with a prominent myoepithelial component among both the myoepithelial cells and cells lining lumens. In addition, we examined the staining of S100, microphthalmia-associated transcription factor (MiTF), keratin cocktail, HMK903, smooth muscle actin (SMA) and epithelial membrane antigen (EMA).
SOX-10 positivity was seen in three of five (60%) cutaneous myoepitheliomas and in the myoepithelial cells of all cutaneous mixed tumors. SOX-10 expression on the cells lining the glandular structures in mixed tumors was variable. All myoepitheliomas and mixed tumors stained positively with S100 and negatively with MiTF. Pan-keratin, HMK903, SMA and EMA showed variable expression.
SOX-10 is a relatively reliable marker for staining cutaneous myoepitheliomas. Cutaneous myoepitheliomas are notoriously difficult to diagnose, and the addition of SOX-10 to the repertoire of stains that can label this tumor is of practical utility. These results further support that cutaneous myoepitheliomas and cutaneous mixed tumors exist on a morphologic and immunophenotypic spectrum.